TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PAIN CONTROL IN FIRST TRIMESTER MEDICAL ABORTION: A Randomized Trial
Brief Summary: This trial will compare two oral analgesic regimens in women undergoing first trimester medical abortion with mifepristone and misoprostol. The primary study outcome is pain.


Options:
A: Arm Label: Opioid; Type: ACTIVE_COMPARATOR; Interventions: Drug: opioid-containing analgesic | Arm Label: Non-Opioid; Type: ACTIVE_COMPARATOR; Interventions: Drug: two over-the-counter analgesics | Intervention Type: DRUG; Name: opioid-containing analgesic; Assigned to Arm(s): Opioid | Intervention Type: DRUG; Name: two over-the-counter analgesics; Assigned to Arm(s): Non-Opioid
B: Arm Label: Patients; Type: N/A; Interventions: N/A
C: Arm Label: Therapeutic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Arm Label: Prophylactic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Prophylactic, Therapeutic
D: Arm Label: Paracetamol/codeine Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: paracetamol 500 mg plus codeine 30 mg preoperative administration | Arm Label: Ibuprofen Group B; Type: ACTIVE_COMPARATOR; Interventions: Drug: ibuprofen 400 mg preoperative administration | Arm Label: Placebo Group C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral tablet preoperative administration | Intervention Type: DRUG; Name: paracetamol 500 mg plus codeine 30 mg preoperative administration; Assigned to Arm(s): Paracetamol/codeine Group A | Intervention Type: DRUG; Name: ibuprofen 400 mg preoperative administration; Assigned to Arm(s): Ibuprofen Group B | Intervention Type: DRUG; Name: Placebo oral tablet preoperative administration; Assigned to Arm(s): Placebo Group C

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PAIN CONTROL IN FIRST TRIMESTER MEDICAL ABORTION: A Randomized Trial
Brief Summary: This trial will compare two oral analgesic regimens in women undergoing first trimester medical abortion with mifepristone and misoprostol. The primary study outcome is pain.


Options:
A: Arm Label: Mifepristone at home 24 hours before miso dosing starts; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone | Arm Label: Mifepristone and first dose of misoprostol simultaneously.; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): Mifepristone at home 24 hours before miso dosing starts | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Mifepristone and first dose of misoprostol simultaneously.
B: Arm Label: ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: ibuprofen | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: ibuprofen; Assigned to Arm(s): ibuprofen
C: Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Therapeutic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Arm Label: Prophylactic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Prophylactic, Therapeutic

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi Center, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Investigate the Efficacy and Safety of RO4995819 Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder Having Inadequate Response to Ongoing Antidepressant Treatment (ARTDeCo)
Brief Summary: This multi-center, randomized, double-blind, placebo-controlled, parallel-group study will investigate the efficacy and safety of RO4995819 as adjunctive therapy in patients with major depressive disorder having inadequate response to ongoing antidepressant treatment. Patients will be randomized to receive once daily doses of 5 mg, 15 or 30 mg of RO4995819 or matching placebo. The anticipated time on study treatment is 6 weeks.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: RO4995819 15 mg; Type: EXPERIMENTAL; Interventions: Drug: RO4995819 | Arm Label: RO4995819 30 mg; Type: EXPERIMENTAL; Interventions: Drug: RO4995819 | Arm Label: RO4995819 5 mg; Type: EXPERIMENTAL; Interventions: Drug: RO4995819 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RO4995819; Assigned to Arm(s): RO4995819 5 mg | Intervention Type: DRUG; Name: RO4995819; Assigned to Arm(s): RO4995819 15 mg | Intervention Type: DRUG; Name: RO4995819; Assigned to Arm(s): RO4995819 30 mg
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
C: Arm Label: Ketamine; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Omega-3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Smoothie 1g Eicosapentaneoic Acid (EPA) and 1g Docoshaexanoic Acid (DHA) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Smoothie 1g Eicosapentaneoic Acid (EPA) and 1g Docoshaexanoic Acid (DHA) | Intervention Type: DIETARY_SUPPLEMENT; Name: Smoothie 1g Eicosapentaneoic Acid (EPA) and 1g Docoshaexanoic Acid (DHA); Assigned to Arm(s): Omega-3, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: OPUS(Optimal Well-being, Development and Health for Danish Children Through a Healthy New Nordic Diet) School Meal Study
Brief Summary: The aim of this randomized crossover study, is to investigate the effect of school meals based on a sustainable New Nordic Diet on growth, learning abilities, well-being, sleep quality, physical activity and risk markers of cardiovascular disease (CVD), type II diabetes and osteoporosis in 8-11 year old Danish school children.

The participating 3rd and 4th grades on 9 selected primary schools will be randomized to either start receiving New Nordic Diet school meals for 3 month(mo) or to eat their habitual school lunch for 3 mo and then crossover for additional 3 mo. All participants will be examined three times; at baseline, after 3 mo and after 6 mo.


Options:
A: Arm Label: NewNordicDiet first; Type: OTHER; Interventions: Other: School meals based on the principles of the New Nordic Diet | Arm Label: NewNordicDiet last; Type: OTHER; Interventions: Other: School meals based on the principles of the New Nordic Diet | Intervention Type: OTHER; Name: School meals based on the principles of the New Nordic Diet; Assigned to Arm(s): NewNordicDiet first, NewNordicDiet last
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Dose; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic exercise program | Arm Label: High dose; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic exercise program | Intervention Type: BEHAVIORAL; Name: Aerobic exercise program; Assigned to Arm(s): High dose, Low Dose
C: Arm Label: "Fortaleça sua Saúde" program; Type: EXPERIMENTAL; Interventions: Behavioral: "Fortaleça sua Saúde" program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: "Fortaleça sua Saúde" program; Assigned to Arm(s): "Fortaleça sua Saúde" program
D: Arm Label: multi-component, multi-level, multi-setting (MMM); Type: EXPERIMENTAL; Interventions: Behavioral: MMM | Arm Label: Health and Nutrition Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health and Nutrition Education | Intervention Type: BEHAVIORAL; Name: MMM; Assigned to Arm(s): multi-component, multi-level, multi-setting (MMM) | Intervention Type: BEHAVIORAL; Name: Health and Nutrition Education; Assigned to Arm(s): Health and Nutrition Education

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: OPUS(Optimal Well-being, Development and Health for Danish Children Through a Healthy New Nordic Diet) School Meal Study
Brief Summary: The aim of this randomized crossover study, is to investigate the effect of school meals based on a sustainable New Nordic Diet on growth, learning abilities, well-being, sleep quality, physical activity and risk markers of cardiovascular disease (CVD), type II diabetes and osteoporosis in 8-11 year old Danish school children.

The participating 3rd and 4th grades on 9 selected primary schools will be randomized to either start receiving New Nordic Diet school meals for 3 month(mo) or to eat their habitual school lunch for 3 mo and then crossover for additional 3 mo. All participants will be examined three times; at baseline, after 3 mo and after 6 mo.


Options:
A: Arm Label: Lifestyle modification; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Healthy Kids-Houston program | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Healthy Kids-Houston program; Assigned to Arm(s): Lifestyle modification | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control
B: Arm Label: NewNordicDiet first; Type: OTHER; Interventions: Other: School meals based on the principles of the New Nordic Diet | Arm Label: NewNordicDiet last; Type: OTHER; Interventions: Other: School meals based on the principles of the New Nordic Diet | Intervention Type: OTHER; Name: School meals based on the principles of the New Nordic Diet; Assigned to Arm(s): NewNordicDiet first, NewNordicDiet last
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Nutrition and exercise education and coping skills training | Intervention Type: BEHAVIORAL; Name: Nutrition and exercise education and coping skills training; Assigned to Arm(s): Intervention
D: Arm Label: Breakfast Skipping; Type: EXPERIMENTAL; Interventions: Behavioral: Breakfast Skipping | Arm Label: Normal Protein Breakfast Meals; Type: EXPERIMENTAL; Interventions: Behavioral: Normal Protein Breakfast Meals | Arm Label: Protein-rich Breakfast Meals; Type: EXPERIMENTAL; Interventions: Behavioral: Protein-rich Breakfast Meals | Intervention Type: BEHAVIORAL; Name: Breakfast Skipping; Assigned to Arm(s): Breakfast Skipping | Intervention Type: BEHAVIORAL; Name: Normal Protein Breakfast Meals; Assigned to Arm(s): Normal Protein Breakfast Meals | Intervention Type: BEHAVIORAL; Name: Protein-rich Breakfast Meals; Assigned to Arm(s): Protein-rich Breakfast Meals

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Open-Label Phase II Study to Assess the Efficacy & Safety of AZD4547 Monotherapy Versus Paclitaxel in Patients With Advanced Gastric Adenocarcinoma (Inc. Adenocarcinoma of the Lower Third of the Oesophagus or the Gastro-Oesophageal Junction)With FGFR2 Polysomy or Gene Amplification.
Brief Summary: The purpose of this study is to assess the efficacy, safety and tolerability of AZD4547 compared with paclitaxel in patients with advanced gastric or lower-oesophageal cancer whose tumours are found to have FGFR2 polysomy or gene amplification.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olaparib, Drug: paclitaxel | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: Placebo | Intervention Type: DRUG; Name: olaparib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Arm A: Lapatinib; Type: EXPERIMENTAL; Interventions: Drug: Lapatinib | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Lapatinib plus capecitabine | Intervention Type: DRUG; Name: Lapatinib; Assigned to Arm(s): Arm A: Lapatinib | Intervention Type: DRUG; Name: Lapatinib plus capecitabine; Assigned to Arm(s): Arm B
C: Arm Label: Arm A (ECF + cetuximab); Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Drug: ECF | Arm Label: Arm B (IC + cetuximab); Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Drug: IC | Arm Label: ARM C (FOLFOX + cetuximab); Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Drug: FOLFOX | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): ARM C (FOLFOX + cetuximab), Arm A (ECF + cetuximab), Arm B (IC + cetuximab) | Intervention Type: DRUG; Name: ECF; Assigned to Arm(s): Arm A (ECF + cetuximab) | Intervention Type: DRUG; Name: IC; Assigned to Arm(s): Arm B (IC + cetuximab) | Intervention Type: DRUG; Name: FOLFOX; Assigned to Arm(s): ARM C (FOLFOX + cetuximab)
D: Arm Label: AZD4547; Type: EXPERIMENTAL; Interventions: Drug: AZD4547 | Arm Label: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel | Intervention Type: DRUG; Name: AZD4547; Assigned to Arm(s): AZD4547 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Paclitaxel

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein, BIIB031, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia A
Brief Summary: The primary objective of the study is to evaluate the safety of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in previously treated pediatric subjects with hemophilia A. Secondary objectives of this study in this study population are as follows: to evaluate the efficacy of rFVIIIFc for prevention and treatment of bleeding episodes; to evaluate and assess the pharmacokinetics (PK) of rFVIIIFc; and to evaluate rFVIIIFc consumption for prevention and treatment of bleeding episodes.


Options:
A: N/A
B: Arm Label: All participants; Type: EXPERIMENTAL; Interventions: Drug: BIIB031 (rFVIIIFc), Drug: FVIII (PK subgroup only) | Intervention Type: DRUG; Name: BIIB031 (rFVIIIFc); Assigned to Arm(s): All participants | Intervention Type: DRUG; Name: FVIII (PK subgroup only); Assigned to Arm(s): All participants
C: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Genetic: AAV5-hFIX | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Genetic: AAV5-hFIX | Intervention Type: GENETIC; Name: AAV5-hFIX; Assigned to Arm(s): Cohort 1, Cohort 2
D: Arm Label: Fixed Weekly Interval; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc), Drug: rFIX | Arm Label: Individualized Interval; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc) | Arm Label: On Demand; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc) | Arm Label: Surgery; Type: EXPERIMENTAL; Interventions: Drug: Factor IX (rFIXFc) | Intervention Type: DRUG; Name: Factor IX (rFIXFc); Assigned to Arm(s): Fixed Weekly Interval, Individualized Interval, On Demand, Surgery | Intervention Type: DRUG; Name: rFIX; Assigned to Arm(s): Fixed Weekly Interval

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein, BIIB031, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia A
Brief Summary: The primary objective of the study is to evaluate the safety of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in previously treated pediatric subjects with hemophilia A. Secondary objectives of this study in this study population are as follows: to evaluate the efficacy of rFVIIIFc for prevention and treatment of bleeding episodes; to evaluate and assess the pharmacokinetics (PK) of rFVIIIFc; and to evaluate rFVIIIFc consumption for prevention and treatment of bleeding episodes.


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, Biological: PEGylated Recombinant Factor VIII | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, Biological: PEGylated Recombinant Factor VIII | Intervention Type: BIOLOGICAL; Name: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method; Assigned to Arm(s): Cohort 1, Cohort 2 | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Cohort 1, Cohort 2
B: Arm Label: Group 1; Type: OTHER; Interventions: Genetic: Gene Transfer, Drug: scAAV2/8-LP1-hFIXco | Intervention Type: GENETIC; Name: Gene Transfer; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: scAAV2/8-LP1-hFIXco; Assigned to Arm(s): Group 1
C: Arm Label: All participants; Type: EXPERIMENTAL; Interventions: Drug: BIIB031 (rFVIIIFc), Drug: FVIII (PK subgroup only) | Intervention Type: DRUG; Name: BIIB031 (rFVIIIFc); Assigned to Arm(s): All participants | Intervention Type: DRUG; Name: FVIII (PK subgroup only); Assigned to Arm(s): All participants
D: Arm Label: Prophylaxis; Type: EXPERIMENTAL; Interventions: Biological: rIX-FP | Arm Label: On-demand; Type: EXPERIMENTAL; Interventions: Biological: rIX-FP | Intervention Type: BIOLOGICAL; Name: rIX-FP; Assigned to Arm(s): On-demand, Prophylaxis

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acute Respiratory Failure After Cardio Thoracic Surgery: Non Invasive Ventilation (VNI) by BIPAP Vision Versus OPTIFLOW System, Comparison.
Brief Summary: The OPTIFLOW ™ use is becoming more common in acute respiratory failure cases, but its place in relation to VNI (Bi-PAP mode) is not yet defined. OPTIFLOW ™ vs the VNI comparison of the use, in the immediate postoperative period, should lead to define the role of each technique and lead to a optimal rationalization of patients management with acute respiratory failure after surgery.


Options:
A: Arm Label: standard oxygen group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard oxygen | Arm Label: High-flow nasal oxygen (HFNO) group; Type: EXPERIMENTAL; Interventions: Procedure: HFNO | Intervention Type: PROCEDURE; Name: standard oxygen; Assigned to Arm(s): standard oxygen group | Intervention Type: PROCEDURE; Name: HFNO; Assigned to Arm(s): High-flow nasal oxygen (HFNO) group
B: Arm Label: BIPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: Non invasive ventilation (VNI) | Arm Label: OPTIFLOW; Type: EXPERIMENTAL; Interventions: Device: Non invasive ventilation | Intervention Type: DEVICE; Name: Non invasive ventilation (VNI); Assigned to Arm(s): BIPAP | Intervention Type: DEVICE; Name: Non invasive ventilation; Assigned to Arm(s): OPTIFLOW
C: Arm Label: HFNC first; Type: ACTIVE_COMPARATOR; Interventions: Device: HFNC followed by conventional nasal cannula | Arm Label: LFS first; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional nasal cannula followed by HFNC | Intervention Type: DEVICE; Name: HFNC followed by conventional nasal cannula; Assigned to Arm(s): HFNC first | Intervention Type: DEVICE; Name: Conventional nasal cannula followed by HFNC; Assigned to Arm(s): LFS first
D: Arm Label: High Flow Conditioned Oxygen Therapy in high risk patients; Type: EXPERIMENTAL; Interventions: Device: High Flow Conditioned Oxygen Therapy in High Risk Patients | Arm Label: Non-invasive mechanical ventilation in High Risk Patients; Type: ACTIVE_COMPARATOR; Interventions: Device: Non-invasive mechanical ventilation | Arm Label: High Flow Conditioned Oxygen Therapy in Low Risk Patients; Type: EXPERIMENTAL; Interventions: Device: High Flow Conditioned Oxygen Therapy in High Risk Patients | Arm Label: Conventional Oxygen Therapy in Low Risk Patients; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional Oxygen Therapy | Intervention Type: DEVICE; Name: High Flow Conditioned Oxygen Therapy in High Risk Patients; Assigned to Arm(s): High Flow Conditioned Oxygen Therapy in Low Risk Patients, High Flow Conditioned Oxygen Therapy in high risk patients | Intervention Type: DEVICE; Name: Non-invasive mechanical ventilation; Assigned to Arm(s): Non-invasive mechanical ventilation in High Risk Patients | Intervention Type: DEVICE; Name: Conventional Oxygen Therapy; Assigned to Arm(s): Conventional Oxygen Therapy in Low Risk Patients

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acute Respiratory Failure After Cardio Thoracic Surgery: Non Invasive Ventilation (VNI) by BIPAP Vision Versus OPTIFLOW System, Comparison.
Brief Summary: The OPTIFLOW ™ use is becoming more common in acute respiratory failure cases, but its place in relation to VNI (Bi-PAP mode) is not yet defined. OPTIFLOW ™ vs the VNI comparison of the use, in the immediate postoperative period, should lead to define the role of each technique and lead to a optimal rationalization of patients management with acute respiratory failure after surgery.


Options:
A: Arm Label: High-flow nasal cannula oxygen (HFNCO); Type: EXPERIMENTAL; Interventions: Device: High-flow Nasal Cannula Oxygen (HFNCO) | Arm Label: standard oxygen therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional oxygen treatment | Intervention Type: DEVICE; Name: High-flow Nasal Cannula Oxygen (HFNCO); Assigned to Arm(s): High-flow nasal cannula oxygen (HFNCO) | Intervention Type: DEVICE; Name: Conventional oxygen treatment; Assigned to Arm(s): standard oxygen therapy
B: Arm Label: Venturi mask; Type: ACTIVE_COMPARATOR; Interventions: Device: Venturi mask | Arm Label: Nasal high-flow; Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal high-flow | Intervention Type: DEVICE; Name: Venturi mask; Assigned to Arm(s): Venturi mask | Intervention Type: DEVICE; Name: Nasal high-flow; Assigned to Arm(s): Nasal high-flow
C: Arm Label: High Flow Conditioned Oxygen Therapy; Type: EXPERIMENTAL; Interventions: Device: Optiflow (Fisher&Paykel) | Arm Label: Standard Oxygen Therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal cannulae or controlled oxygen concentration mask | Intervention Type: DEVICE; Name: Optiflow (Fisher&Paykel); Assigned to Arm(s): High Flow Conditioned Oxygen Therapy | Intervention Type: DEVICE; Name: Nasal cannulae or controlled oxygen concentration mask; Assigned to Arm(s): Standard Oxygen Therapy
D: Arm Label: BIPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: Non invasive ventilation (VNI) | Arm Label: OPTIFLOW; Type: EXPERIMENTAL; Interventions: Device: Non invasive ventilation | Intervention Type: DEVICE; Name: Non invasive ventilation (VNI); Assigned to Arm(s): BIPAP | Intervention Type: DEVICE; Name: Non invasive ventilation; Assigned to Arm(s): OPTIFLOW

Answer: D